Digital twins, synthetic patient data, and in-silico trials: can they empower paediatric clinical trials?

Area of Science:

• Digital health innovations
• Clinical trial methodology
• Pediatric research

Background:

• Paediatric clinical trials often face early discontinuation due to low patient enrollment, leading to inadequate statistical power.
• Current trial limitations include high costs and potential exposure of children to unproven therapies.
• Advances in digital health offer alternatives like digital twins, synthetic patient data, and in-silico trials.

Purpose of the Study:

• To propose the integration of virtual patient data in paediatric clinical trials.
• To highlight the potential benefits of using digital innovations to empower paediatric research.
• To address the challenges and ethical considerations associated with virtual patient data adoption.

Main Methods:

• This viewpoint discusses the application of virtual patient data, including digital twins, synthetic data, and in-silico trials.
• It explores how these digital tools can be leveraged within the context of paediatric research.
• The authors review the advantages and potential drawbacks of incorporating virtual patient data.

Main Results:

• Virtual patient data can decrease children's exposure to potentially ineffective or risky interventions.
• Utilizing virtual data can shorten trial durations, enabling faster assessment of intervention safety and effectiveness.
• This approach may lead to more personalized treatments, reduced costs, and accelerated drug approvals for paediatric populations.

Conclusions:

• Virtual patient data offers significant advantages for paediatric clinical trials, including enhanced efficiency and safety.
• Widespread adoption requires careful consideration and resolution of ethical and regulatory issues, such as data privacy and security.
• Ensuring the safety and sustainability of digital data innovations is paramount before their broad implementation.